Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy TrialsPoornima Saha, Meredith M Regan, Olivia Pagani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial CancerPanagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, et al.British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.The New England Journal of Medicine|June 3, 2014
Adjuvant exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Barbara A Walley, et al.Pageof 2